JEB Technologies Ltd is excited to be joining forces with the Association of British HealthTech Industries (ABHI) at Medica 2023.
With a staggering 76% increase in visitor numbers from the previous year, MEDICA has solidified its status as the world’s leading Medical trade fair, attracting close to 100,000 professionals from around the world. Taking place from 13th-16th November 2023, this year’s event marks a significant milestone in the return of in-person gatherings on the health technology calendar.
The ABHI will once again be leading the UK’s most visible Pavilion of UK HealthTech companies at
the show, offering a dedicated platform to showcase the strengths of the industry on the global stage. The event, which takes place in Düsseldorf, Germany, offers a valuable opportunity for UK companies to network with potential clients and partners from around the world, and to explore new markets and opportunities. JEB Technologies Ltd will be joining the ABHI UK Pavilion at Medica 2023 to showcase a variety of novel devices and highlight our in-house capabilities.
About JEB Technologies
With over 50 years of experience, JEB Technologies prides itself in providing customers with state of the art, innovative design and manufacturing solutions. As a single source manufacturer covering multiple sectors, JEB will work with you to provide an end-to- end product development service for both new and existing products and medical devices. JEB welcomes the opportunity to be involved from early development stage to assess, advise, expand and prototype ideas, using extensive experience to optimise products for manufacture. This early on involvement can reduce time to market, as well as reduce the overall tooling and manufacturing cost.
JEB Technologies have facilities for tool and jig design with in-house tooling facilities for both metal and plastic components and their subsequent assembly. The wide range of in-house manufacturing capabilities and skilled engineers are supported by quality management and regulatory support for the validation of manufacturing processes and critical control systems required for the medical industry.
Products and devices
One product that will be on display at MEDICA is the CamPROBE device (Cambridge Prostate Biopsy Device) , which aims to provide a simple and low-cost alternative to the current methods of acquiring prostate tissue to subsequently diagnose the presence of prostate cancer. The device is intended to facilitate biopsies through the transperineal route using a simultaneous local anaesthetic delivery through an integrated coaxial needle. It is an alternative system to the transrectal approach and to other transperineal devices and only needs two body puncture points, resulting in low pain scores, enhanced patient comfort and patient acceptability (Journal of Clinical Urology 2020,Vol 13 (5) 364-370). With over 2 million biopsies performed each year in Europe and North America[1], JEB anticipate that CamPROBE will be adopted worldwide to facilitate prostate cancer detection.
JEB will also be showcasing Safira, a new technology for regional anaesthesia making it a one person procedure. The unique engineered in safety solution monitors and limits injection pressure, improving patient safety by reducing risk of patient nerve damage resulting from the procedure. Another product expected to be on display is Transicap, a product used to measure gut transit time in children and adults, still in the development stage.
MEDICA 2023
Paul Benton, Managing Director International, ABHI, said “MEDICA 2023 is set to be a remarkable showcase of leading and innovative companies from around the world, and we are incredibly proud to once again host an exceptional line up. Together our exhibitors will spotlight the strengths of UK HealthTech while actively seeking new global partnerships and collaborations.”
MEDICA is taking place from 13 – 16th November 2023 and throughout the show, JEB Technologies Ltd will be located at 16H52.2 .
[1] Borghesi M, Ahmed H, Nam R, Schaeffer E, Schiavina R, Taneja S, et al. Complications after systematic, random, and image-guided prostate biopsy. Eur Urol. 2017;71:353–65.